Regentis Biomaterials Ltd. (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.
The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes expanding physician familiarity with the technology will support adoption as the product enters broader clinical use.
The announcement underscores the company’s commitment to addressing a significant unmet medical need. According to Regentis, approximately 470,000 cases of knee cartilage repair occur annually in the U.S., where no off-the-shelf treatment is currently available. GelrinC, a cell-free hydrogel implant, is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The product received CE Mark approval, enabling its commercialization in Europe.
The training program is expected to enhance surgeon proficiency with the GelrinC procedure, which the company believes will facilitate adoption and integration into clinical practice. By establishing Centers of Excellence across Europe, Regentis aims to create a network of knowledgeable physicians who can train peers and share best practices.
For more details, the full press release is available at https://ibn.fm/QOWWK. Regentis Biomaterials is a regenerative medicine company focused on developing tissue repair solutions, with GelrinC as its lead product. Investors can find the latest news and updates relating to RGNT in the company’s newsroom at https://ibn.fm/RGNT.
The company’s strategy reflects a broader trend in orthopedics toward minimally invasive, cell-free approaches that simplify surgical procedures and reduce recovery times. As Regentis moves forward with its European launch, the success of the training program will be critical in building the clinical evidence and physician confidence needed to drive adoption.
